TransCode Therapeutics, Inc. (RNAZ)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20260 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to TransCode Therapeutics, Inc.’s names, not what it holds today.
2 published
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| May 23, 2024 | 2024/0167022 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | Pharmaceuticals | Transcode Therapeutics, Inc. |
| Feb 8, 2024 | 2024/0042070 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | Pharmaceuticals | Transcode Therapeutics, Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.